Indivior PLC (LON:INDV)‘s stock had its “buy” rating restated by Numis Securities Ltd in a report released on Friday, October 20th. They currently have a GBX 500 ($6.60) price objective on the specialty pharmaceutical company’s stock. Numis Securities Ltd’s price target points to a potential upside of 50.60% from the company’s previous close.
A number of other brokerages also recently issued reports on INDV. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 400 ($5.28) price objective on shares of Indivior PLC in a research report on Friday, September 15th. Citigroup Inc. reissued a “neutral” rating and set a GBX 280 ($3.69) target price on shares of Indivior PLC in a research report on Tuesday, September 5th. Royal Bank Of Canada raised shares of Indivior PLC to an “outperform” rating and boosted their target price for the stock from GBX 390 ($5.15) to GBX 470 ($6.20) in a research report on Friday, July 28th. Finally, Jefferies Group LLC dropped their target price on shares of Indivior PLC from GBX 540 ($7.13) to GBX 358 ($4.72) and set a “buy” rating on the stock in a research report on Friday, September 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of GBX 400.50 ($5.29).
Shares of Indivior PLC (LON INDV) opened at 332.00 on Friday. The company has a 50 day moving average of GBX 326.64 and a 200-day moving average of GBX 336.52. Indivior PLC has a 12-month low of GBX 246.50 and a 12-month high of GBX 421.50. The company’s market cap is GBX 2.39 billion.
WARNING: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/29/indivior-plc-indv-rating-reiterated-by-numis-securities-ltd.html.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.